Claims for Patent: 10,633,454

Summary for Patent: 10,633,454

Title:	Expression of modified glycoproteins and glycopeptides
Abstract:	The present invention provides recombinant cells that contain a genetic modification to at least one mannosyl transferase gene. As a result of the modification the cells produce a glycoprotein or glycopeptide that has an N-linked glycan profile that is simplified or more easily humanized. The glycoprotein or glycopeptide can have at least 25% fewer high mannose structures on than the glycoprotein or glycopeptide produced by a reference cell. In some embodiments the modification is a deletion or disruption of a mannosyl transferase gene, which can be in an alg3 gene. Therefore, the proteins produced are more useful for the production of therapeutic glycoproteins than those produced by species having foreign or plant-like patterns of glycosylation. The invention also provides compositions of the glycoproteins or glycopeptides and methods of making them.
Inventor(s):	Caiazza; Nicky C. (Rancho Santa Fe, CA)
Assignee:	Conagen Inc. (Bedford, MA)
Application Number:	15/967,202
Patent Claims:	1. A recombinant cell of the family Thraustochytriaceae comprising: a nucleic acid molecule encoding a heterologous glycoprotein or glycopeptide; a genetic modification to one or more gene(s) encoding a mannosyl transferase, wherein the cell produces the heterologous glycoprotein or glycopeptide having an N-linked glycan profile comprising at least 50% paucimannose N-glycan structures. 2. The cell of claim 1 wherein the genetic modification is selected from the group consisting of: a deletion, an insertion, a replacement, and a disruption. 3. The cell of claim 1 wherein the genetic modification is a deletion and the mannosyl transferase is an alpha-1,3-mannosyl transferase. 4. The cell of claim 1 wherein the mannosyl transferase is of the class EC 2.4.1.258. 5. The cell of claim 1 wherein the heterologous glycoprotein or glycopeptide is an antibody. 6. The cell of claim 1 wherein the heterologous glycoprotein is selected from the group consisting of: trastuzumab, eculizumab, natalizumab, cetuximab, omalizumab, usteinumab, panitumumab, and adalimumab, or a functional fragment of any of them. 7. The cell of claim 3 wherein the heterologous glycoprotein or glycopeptide has an N-linked glycan profile having at least 50% fewer high mannose N-linked glycans than the N-linked glycan profile from a corresponding cell that does not comprise the mannosyl transferase deletion. 8. The cell of claim 1 wherein the glycoprotein or glycopeptide has an N-linked glycan profile having less than 20% high mannose structures. 9. The cell of claim 1 from a genus selected from the group consisting of: Aurantiochytrium, Schizochytrium, and Thraustochytrium. 10. The cell of claim 3 wherein the glycoprotein or glycopeptide comprises at least 25% fewer xylose moieties than the cell that does not comprise the mannosyl transferase deletion. 11. The cell of claim 3 wherein the cell is an Aurantiochytrium sp. 12. The cell of claim 10 wherein the glycoprotein or glycopeptide does not comprise N-linked glycans comprising xylose. 13. The cell of claim 1 wherein the N-linked glycans comprise at least 80% paucimannose structures. 14. The cell of claim 1 wherein N-linked glycans comprise at least 70% Man3. 15. The cell of claim 1 wherein the N-linked glycan profile comprises at least 70% fewer high mannose structures compared to a reference cell not comprising the genetic modification. 16. A method of producing a glycoprotein or glycopeptide that comprises a simplified N-glycan profile comprising: a. performing a genetic modification to a gene that encodes a mannosyl transferase in a Thraustochytriaceae host cell that comprises a nucleic acid that encodes a heterologous glycoprotein or glycopeptide; b. cultivating the host cell; c. harvesting the heterologous glycoprotein or glycopeptide from the cell that has an N-linked glycan profile comprising at least 50% paucimannose structures. 17. The method of claim 16 wherein the mannosyl transferase is an alpha-1,3-mannosyl transferase. 18. The method of claim 17 wherein the mannosyl transferase is of the class EC 2.4.1.258. 19. The method of claim 17 wherein the genetic modification is a deletion, and the glycoprotein or glycopeptide is an antibody. 20. The cell of claim 17 wherein the glycoprotein or glycopeptide is selected from the group consisting of: trastuzumab, eculizumab, natalizumab, cetuximab, omalizumab, usteinumab, panitumumab, and adalimumab, or a functional fragment of any of them. 21. The method of claim 16 wherein the glycoprotein or glycopeptide comprises at least 50% N-linked glycans that are paucimannose. 22. The method of claim 16 wherein the N-linked glycan profile comprises less than 25% high mannose structures. 23. The method of claim 16 wherein the Thraustochytriaceae cell is selected from the group consisting of: Aurantiochytrium, Schizochytrium, and Thraustochytrium. 24. The method of claim 16 wherein the glycoprotein or glycopeptide comprises at least 25% fewer xylose moieties than a reference cell that does not comprise the mannosyl transferase deletion. 25. The method of claim 23 wherein the Thraustochytriaceae cell is an Aurantiochytrium sp. 26. The method of claim 23 wherein the glycoprotein or glycopeptide does not comprise N-linked glycans comprising xylose. 27. The method of claim 16 wherein more than 75% of the N-linked glycans are paucimannose. 28. The method of claim 27 wherein the paucimannose structures comprise at least 30% Man3 structures.

Details for Patent 10,633,454

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2036-11-01
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2036-11-01
Genentech, Inc.	XOLAIR	omalizumab	For Injection	103976	06/20/2003		2036-11-01
Genentech, Inc.	XOLAIR	omalizumab	Injection	103976	09/28/2018		2036-11-01
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002		2036-11-01